Volume 20 No 22 (2022)
 Download PDF
Impact of L-arginine as an adjuvant drug in smear-positive TB cases
Kumar Raja Madasu, Dr. Virendra Singh , Dr. Jyotsna SharmaDr. Jyotsna Sharma
Smear-positive tuberculosis (TB) is a global public health issue. Standard treatment regimens have medication resistance and extensive treatment duration. Due to its immunomodulatory and antiinflammatory properties, L-arginine may be an adjuvant therapy for TB. This study examined Larginine as an adjuvant medication in smear-positive TB patients. From December 2020 to June 2021, a tertiary care hospital in Mathura, K.M Medical College & Hospital, conducted a randomised controlled experiment. 150 patients were randomly randomised to L-arginine and 150 to placebo and evaluated for clinical and biochemical data. Adding L-arginine to anti-TB medication considerably improved clinical outcomes. In conclusion, L-arginine supplementation may be an effective adjuvant therapy for smear-positive TB patients, increasing treatment outcomes, constitutional symptoms, CRP, and cough. Further research is needed to validate these findings and evaluate L-arginine as a TB treatment supplement.
Copyright © Neuroquantology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.